MindWalk Launches Nanobody Platform Targeting $50B Bispecific Therapy Market
Event summary
- MindWalk introduced B Cell Llama™, a nanobody discovery platform for bispecific and cell therapies.
- Bispecific antibody market projected to reach $50B by 2030, with cell therapy adding billions more.
- Peer-reviewed study showed VHH nanobodies achieved 10-25x potency in multivalent formats.
- LensAI™ integrates AI across discovery workflows from immunogen design to candidate triage.
The big picture
MindWalk's B Cell Llama™ targets a critical gap in bispecific antibody development, where VHH nanobodies offer modularity and potency advantages. The platform aligns with industry shifts toward AI-guided discovery and multispecific therapeutic formats. With over 15 molecules advanced to clinical stage using its technologies, MindWalk is positioning itself as a key player in next-generation biologic drug development.
What we're watching
- Market Adoption
- How quickly B Cell Llama™ can capture share in the rapidly growing bispecific therapy market.
- Technical Validation
- Whether preclinical findings on VHH nanobody potency and immune-priming translate to clinical success.
- Pipeline Progression
- The pace at which MindWalk advances its current programs, including dengue, influenza, and longevity therapeutics.
Related topics